Last €16.64 EUR
Change Today -0.61 / -3.54%
Volume 167.6K
NANO On Other Exchanges
Symbol
Exchange
EN Paris
As of 11:35 AM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

nanobiotix (NANO) Snapshot

Open
€17.30
Previous Close
€17.25
Day High
€17.70
Day Low
€16.20
52 Week High
02/13/14 - €30.28
52 Week Low
12/20/13 - €4.57
Market Cap
217.4M
Average Volume 10 Days
140.5K
EPS TTM
--
Shares Outstanding
13.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOBIOTIX (NANO)

Related News

No related news articles were found.

nanobiotix (NANO) Related Businessweek News

No Related Businessweek News Found

nanobiotix (NANO) Details

Nanobiotix S.A., a clinical-stage nanomedicine company, engages in the development of tools for the treatment of cancer. Its product pipeline includes NanoXray products comprising NBTXR3 nanoparticles that are designed for direct injection into the tumor; NBTX-IV nanoparticles designed for intravenous injection to reach the tumor and the surrounding tissue; and NBTX-TOPO nanoparticles, a gel applied during surgery after removal of the tumor in various types of breast cancer, brain tumors, and retroperitoneal soft tissue sarcomas. The company also develops nanoMag magnetic particles for treatment and diagnostic of cancer; and nanoPDT laser activated nanoparticles for the treatment of cancer. It has a licensing contract with PharmaEngine, Inc. for the development of NBTXR3; and business and development collaboration with Malaysian Biotech Corp. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

40 Employees
Last Reported Date: 05/1/14
Founded in 2003

nanobiotix (NANO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nanobiotix (NANO) Key Developments

Nanobiotix Announces Revenue Results for the Second Quarter and First Half of 2014

Nanobiotix announced revenue results for the second quarter and first half of 2014. For the quarter, the company reported revenue was EUR 48,596 against EUR 48,569 a year ago. The company reported revenue was EUR 93,939 for the first half of 2014.

Nanobiotix SA Presents at Proactive Investors One2One Forum, Jun-12-2014

Nanobiotix SA Presents at Proactive Investors One2One Forum, Jun-12-2014 . Venue: Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB, United Kingdom.

NANOBIOTIX Announces the Completion of Phase I Results of its Lead NanoXray Product, NBTXR3

NANOBIOTIX announced the completion of the first in human study of its lead NanoXray product, NBTXR3, which will be presented on June 2, 2014 at the American Society of Clinical Oncology (ASCO) annual meeting. The Phase I clinical study established that intratumoral injection of NBTXR3 followed by radiotherapy has a good safety profile in patients with locally advanced soft tissue sarcoma (STS), who have an important risk of relapse and few treatment options. These results allow Nanobiotix to proceed to the pivotal phase, which the final step is leading to registration (CE mark). The study showed that promising signs of antitumor activity for different sarcoma subtypes were observed. Interestingly, tumor shrinkage and pathological response were observed in well-known refractory tumors. All patients underwent a wide surgical resection. This optimal surgery impacts the local recurrence rate, improving patient prognosis since local disease control prolongs progression free survival and overall survival in high grade sarcomas. The study enrolled 20 patients who received a single intratumoral injection of NBTXR3, at escalating volumes, followed by standard radiotherapy (50Gy RTx), as indicated in this clinical setting. Primary endpoints included feasibility of the intratumoral implantation and safety. Secondary endpoints focused on the efficacy such as pathological response and RECIST (Response Evaluation Criteria In Solid Tumors) response, including tumor volume evaluation. Moreover, IntraTumoral permanence of NBTXR3 and operability were assessed. Key findings: Feasibility of the NBTXR3 injection within the tumor mass across different tumor types and volumes (from 55.06ml to 3682.56ml) was demonstrated; No leakage of NBTXR3 to the surrounding healthy tissues was confirmed; Persistence of NBTXR3 during all sessions of radiotherapy: optimal bioavailability over time; Appropriate dispersion of the product within the tumor: diffusion in 3 dimensions; Very good tolerance and local safety of the product at volume 2.5%, 5%, 10% and 20% was observed; Promising signs of antitumor activity were observed in different sarcoma subtypes, such as undifferentiated sarcoma, rhabdomyosarcoma, and synovial sarcoma; and The recommended volume for the pivotal study is 10%. The injection procedure was performed under local anesthesia and pre-medication with analgesic and sedative products. This first step of the clinical development demonstrated the feasibility of NBTXR3 intratumor injection at the 3 first volume levels, followed by radiotherapy. The treatment was safe. No early dose-limiting toxicity (DLT) was observed. Patients received the complete planed radiotherapy scheduled and dose. No grade 3-4 toxicity related to NBTXR3 occurred. Main grade 1-2 adverse events included injection pain/reaction, pyrexia, abdominal pain, pruritus and paresthesia. Results confirmed that a single injection provides adequate bioavailability of NBTXR3 within the tumor over the five weeks of radiotherapy. No leakage of NBTXR3 to the healthy tissues was observed. Further, the evaluation demonstrated the permanence of NBTXR3 within the tumor, before surgery, i.e. 6 weeks after the end of the radiotherapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NANO:FP €16.64 EUR -0.61

NANO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NANO.
View Industry Companies
 

Industry Analysis

NANO

Industry Average

Valuation NANO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 114.4x
Price/Book 56.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 138.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOBIOTIX, please visit www.nanobiotix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.